Committees

Life sciences investment

Inquiry

With MSD cancelling its £1 billion ongoing manufacturing site in Kings Cross, AstraZeneca pausing its £200 million investment in its Cambridge site, and the latter upgrading its US listing, the Science, Innovation and Technology Committee is launching a call for evidence on UK life sciences competitiveness.

This follows an initial emergency session, where it heard from representatives from MSD and AstraZeneca, as well as the ABPI, and from officials and ministers, including Minister for Science, Research and Innovation, Lord Patrick Vallance. 

The call for written evidence will examine the competitiveness of the UK’s life sciences sector, barriers to innovation for medicines in the UK, issues with pricing uptake and access, and the impact of other countries’ policies.

Read the call for evidence here:

Upcoming events

View all events

No upcoming events scheduled

Past events

Tuesday 28 October 2025
9:00am Private
9:45am Public
Oral evidence session 28 October 2025
Innovation showcase - Oral evidence
9:30am
  • Emily Hyett (Group Product Manager at Yoti)
Life sciences investment - Oral evidence
9:45am
  • Dr Sam Roberts (Chief Executive at NICE)
10:30am
  • The Lord Vallance of Balham KCB (Minister for Science, Research and Innovation at Department for Science, Innovation and Technology)
  • Steve Bates (Executive Chairman at Office for Life Sciences)
  • Dr Zubir Ahmed MP (Parliamentary Under-Secretary of State at Department of Health and Social Care)
Room 8, Palace of Westminster

Contact us

We receive a significant number of emails each day. All requests and invitations are considered but we do not respond directly to everyone. Please be aware, the committee does not look at individual cases or specific complaints.